Diabetes software company Glooko has acquired Monarch Medical Technologies in a move that will help the company expand its diabetes care provision into the inpatient glucose management segment.
Through the acquisition, the terms of which have not been publicly disclosed, Glooko will inherit Monarch’s EndoTool Glucose Management System. Used in hospitals to help manage blood glucose levels in critically ill patients, the platform received US Food and Drug Administration (FDA) approval in 2006.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Glooko’s diabetes platform is used by clinicians and healthcare facilities to link medical and connected devices used by diabetics into a singular platform. Adding EndoTool to the platform will further support the company’s efforts to deliver a full-spectrum ‘hospital-to-home’ diabetes solution to improve patient outcomes and streamline operational workflows, according to Glooko’s CEO Mike Alvarez.
Glooko’s chief medical and strategy officer Mark Clements commented: “By integrating EndoTool with Glooko’s outpatient platform, we believe we will be better able to ensure safer care transitions for people with diabetes, help hospitals meet quality and regulatory requirements, and deliver measurable improvements in patient outcomes across the continuum.”
Based in California, Glooko’s acquisition of Monarch marks a continuation of the company’s efforts to develop its platform and expand its global footprint. In November 2024, Glooko completed a $100m Series F financing round to expand into the Middle East and Asia.
At the start of this year, Glooko partnered with Danish digital therapeutics company Hedia to launch a combined diabetes care technology provision in the UK to enhance support for diabetic patients who require bolus insulin dosing support in their daily management.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThroughout 2025, Glooko has also continued adding to its existing roster of over 200 integrated devices, including an integration with Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) device in a move that broadens the reach of Glooko’s platform to around 4.5 million patients who use Abbott’s device.
The global diabetes population is projected to hit 643 million by 2030, as per data from the International Diabetes Federation.
